Back to top

Incyte announces new data from STOP-HS clinical trial program at EADV

Incyte (INCY) announced new 24-week interim data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 i...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Incyte Corporation (INCY)